Denali Capital Acquisition Corp. prices $75M IPO, upsized to $82.5M including over-allotment

Semnur Pharmaceuticals, Inc.

IPO of 7,500,000 units at $10.00/unit, plus over-allotment of 750,000 units, for total 8,250,000 units.
Gross proceeds $82.5M from IPO and $5.1M from private placement of 510,000 units to sponsor.
Trust account funded with $84.15M; proceeds held until business combination or redemption.
Appoints Huifeng Chang, Jim Mao, Kevin D. Vassily as independent directors; board classified three classes.
Units (DECAU), Class A shares (DECA), and warrants (DECAW) listed on Nasdaq.

item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Huifeng Chang

Director

SMNR · Semnur Pharmaceuticals, Inc.

Effective: 2022-04-06
Filed: April 12, 2022, 7:59 PM ET

Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.

Appointed

Jim Mao

Director

SMNR · Semnur Pharmaceuticals, Inc.

Effective: 2022-04-06
Filed: April 12, 2022, 7:59 PM ET

Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.

Appointed

Kevin D. Vassily

Director

SMNR · Semnur Pharmaceuticals, Inc.

Effective: 2022-04-06
Filed: April 12, 2022, 7:59 PM ET

Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Huifeng Chang was appointed as Director at Semnur Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jim Mao was appointed as Director at Semnur Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin D. Vassily was appointed as Director at Semnur Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.

View on SEC.gov

Semnur Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001575872-22-000269

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.